The clinical trial evidence on duration The landmark STEP trials for semaglutide and SURMOUNT trials for tirzepatide provide the clearest data on what happens at different treatment durations
The results were revealing
See the side effects section and speak with a qualified clinician
NICE guidelines (NG28) recommend GLP-1 receptor agonists for type 2 diabetes in specific circumstances, typically in combination with other treatments when certain criteria are met, including BMI thresholds
This modification uniquely induces structural rearrangements associated with amyloidogenic conversion, in contrast to other post-translational modifications on Cys10, such as, S-cysteinylation or S-glutathionylation, that do not significantly alter the native fold [22]
When you do that, oftentimes you make bad decisions, because a lot of this stuff is better treated upstream or from a more global perspective